The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Bronchiectasis is a chronic airway disease characterised by a vicious cycle of persistent bacterial colonization,inflammation and progressive tissue destruction.Patients with bronchiectasis frequently developed acute exacerbations characterised by acute worsening requiring changes in concomitant use of medication,with attendant adverse effects on their morbidity and health-related quality of life. The detailed pathogenesis of exacerbations of bronchiectasis, however, remains poorly understood.
Recent data suggested that airway infection and inflammation are important drivers of exacerbations,therefore the imbalance between chronic bacterial infection and host immune response may result in bronchiectasis exacerbations. Viral infection may be an important factor that leads to this events.It has been established that respiratory viruses are mainly responsible for the exacerbations of other chronic respiratory diseases, i.e. asthma, COPD and cystic fibosis. However, the data regarding prospective studies that sought to investigate the roles of viruses in acute exacerbation of bronchiectasis are lacking. Furthermore,the associations between viruses and bacteria during exacerbation need to be assessed. This study targets at indentifying the frenquency of common viral infections in adults with non-cystic fibrosis bronchiectasis and may shed light on the effects they have on clinical parameters,i.e. the length of exacerbated symptom to recovery,lung function, pulmonary inflammation, bacterial load and quality of life.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Rongchang Chen, MD
- Telefonnummer: 020-83062718
- E-Mail: Chenrc@vip.163.com
Studieren Sie die Kontaktsicherung
- Name: Nanshan Zhong, MD
- Telefonnummer: 020-83062718
- E-Mail: nanshan@vip.163.com
Studienorte
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Rekrutierung
- The First Affiliated Hospital of Guangzhou Medical University
-
Kontakt:
- Rongchang Chen, MD
- Telefonnummer: 020-83062718
- E-Mail: Chenrc@vip.163.com
-
Kontakt:
- Nanshan Zhong, MD
- Telefonnummer: 020-83062718
- E-Mail: nanshan@vip.163.com
-
Unterermittler:
- Yonghua Gao, PHD
-
Unterermittler:
- Gang Xu, PHD
-
Unterermittler:
- Weijie Guan, PHD
-
Unterermittler:
- Zhiya Lin, PHD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Age ≥ 18 years
- HRCT-diagnosed Bronchiectasis
- Capable of providing written informed consent
Exclusion Criteria:
- Patient judged to have poor compliance
- Cystic fibrosis bronchiectasis
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Bronchiectasis,stable
A patient was defined as stable if there was no exacerbation for the previous 4 wk
|
|
Bronchiectasis,exacerbations
Bronchiectasis exacerbations were defined by subjective and persistent(>24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances, or changes in chest auscultation
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The prevalence of respiratory virus infection in adults with bronchiectasis during a pulmonary exacerbation and when clinically stable.
Zeitfenster: 1 year
|
Respiratory viruses in the nasal swab and sputum will be identified using the polymerase chain reaction(PCR)technique when clinically stable and during exacerbation.The following viruses will be tested for:influenza A,B(including influenza A H1N1),respiratory syncytial virus(RSV),Enterovirus,Parainfluenza 1-4,Rhinovirus,human Coronaviruses(subtypes OC43、229E、HKU1),human metapneumovirus,adenovirus, human bocavirus,chlamydia,mycoplasma.
|
1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The effect of respiratory virus infection on systemic and pulmonary inflammatory markers.
Zeitfenster: 1 year
|
Systemic and airway inflammatory cytokines including IL-1β、IL-6、IL-8、TNF-a were measured using a commercial multiplex bead-based assay.
|
1 year
|
|
The effect of respiratory virus on lung function
Zeitfenster: 1 year
|
Spirometric indices in the present study is referred to as forced expiratory vilume in 1s(FEV1),forced vital capacity(FVC).Spirometry tests are carried out using a spirometer (COSMED, QUARK PFT, Italy).
All operation procedures meet the joint recommendation by ATS and ERS.
A total of at least 3 (not more than 8) spirometric maneuvers are performed, with the variation between the best two maneuvers of <5% or 200ml in FVC and FEV1.
The maximal values of FVC and FEV1 are reported.
|
1 year
|
|
The effect of respiratory virus infection on the bacterial load in bronchiectasis.
Zeitfenster: 1 year
|
Type of bacterial infection, also referred to as potentially pathogenic organisms, and bacterial load, as expressed in cfu per mililiter
|
1 year
|
|
Time to recovery of respective symptom
Zeitfenster: 1 year
|
The time from exacerbation onset by which a 3-d moving average was equal to or exceeded the baseline value
|
1 year
|
|
The effect of respiratory virus on quality of life in patients with bronchiectasis
Zeitfenster: 1 year
|
Quality of life in patients with bronchiectasis were measured by St.George Respiratory Questionnaire、Leicester Cough Questionnaire and COPD assessment test during exacerbations,and then compared between virus-postive and virus-negative patients
|
1 year
|
|
To investigate if upper respiratory tract symptoms are associated with viral infections.
Zeitfenster: 1 year
|
1 year
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Nanshan Zhong, MD, The First Affiliated Hospital of Guangzhou Medical University
- Hauptermittler: Rongchang Chen, MD, The First Affiliated Hospital of Guangzhou Medical University
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2009CB522109
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .